Bioceltix S.A.

WSE:BCX Rapporto sulle azioni

Cap. di mercato: zł373.3m

Bioceltix Performance dei guadagni passati

Il passato criteri di controllo 0/6

Bioceltix's earnings have been declining at an average annual rate of -30.7%, while the Biotechs industry saw earnings growing at 7.7% annually.

Informazioni chiave

-30.7%

Tasso di crescita degli utili

-12.1%

Tasso di crescita dell'EPS

Biotechs Crescita del settore56.3%
Tasso di crescita dei ricavin/a
Rendimento del capitale proprio-35.0%
Margine netton/a
Prossimo aggiornamento sui guadagni25 Nov 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn Rate

Jun 15
We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn Rate

Will Bioceltix (WSE:BCX) Spend Its Cash Wisely?

Jan 19
Will Bioceltix (WSE:BCX) Spend Its Cash Wisely?

We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn Rate

Sep 21
We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn Rate

We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn Rate

May 09
We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn Rate

Ripartizione dei ricavi e delle spese

Come Bioceltix guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

WSE:BCX Ricavi, spese e utili (PLN Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 240-16170
31 Mar 240-15160
31 Dec 230-14140
30 Sep 230-13120
30 Jun 230-12110
31 Mar 230-1090
31 Dec 220-980
30 Sep 220-870
31 Mar 220-550

Guadagni di qualità: BCX is currently unprofitable.

Margine di profitto in crescita: BCX is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: Insufficient data to determine if BCX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerare la crescita: Unable to compare BCX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: BCX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Rendimento del capitale proprio

ROE elevato: BCX has a negative Return on Equity (-35.02%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate